Skip to main content

Oxidative Stress in Diabetic Nephropathy

Buy Article:

$68.00 + tax (Refund Policy)

Diabetic nephropathy is a leading cause of end-stage renal failure worldwide. Its morphologic characteristics include glomerular hypertrophy, basement membrane thickening, mesangial expansion, tubular atrophy, interstitial fibrosis and arteriolar thickening. All of these are part and parcel of microvascular complications of diabetes. A large body of evidence indicates that oxidative stress is the common denominator link for the major pathways involved in the development and progression of diabetic micro- as well as macro-vascular complications of diabetes. There are a number of macromolecules that have been implicated for increased generation of reactive oxygen species (ROS), such as, NAD(P)H oxidase, advanced glycation end products (AGE), defects in polyol pathway, uncoupled nitric oxide synthase (NOS) and mitochondrial respiratory chain via oxidative phosphorylation. Excess amounts of ROS modulate activation of protein kinase C, mitogen-activated protein kinases, and various cytokines and transcription factors which eventually cause increased expression of extracellular matrix (ECM) genes with progression to fibrosis and end stage renal disease. Activation of renin-angiotensin system (RAS) further worsens the renal injury induced by ROS in diabetic nephropathy. Buffering the generation of ROS may sound a promising therapeutic to ameliorate renal damage from diabetic nephropathy, however, various studies have demonstrated minimal reno-protection by these agents. Interruption in the RAS has yielded much better results in terms of reno-protection and progression of diabetic nephropathy. In this review various aspects of oxidative stress coupled with the damage induced by RAS are discussed with the anticipation to yield an impetus for designing new generation of specific antioxidants that are potentially more effective to reduce reno-vascular complications of diabetes.





Keywords: 3-deoxyglucosone; Angiotensin; Complications Trial (DCCT); Diabetic Nephropathy; Glomerular hyperfiltration; Hyperglycemia; MITOCHONDRIAL ORIGIN; Microalbuminuria; NAD(P)H oxidase; NFκB; Oxidative Stress; PENTOSE PHOSPHATE PATHWAY; REDOX REGULATION; TETRAHYDROBIOPTERIN; XANTHINE OXIDOREDUCTASE; bioavailability; catachysmically; cytosolic subunit; diabetic nephropathy; diphenylene iodinium; endothelial-targeted; gluthathione peroxide; glycerol phosphate; juxtaglomerular apparatus; microalbuminuria; microvascular; nevertheless; normoglycemic; oligosaccharyl; peroxynitrite; plasmalemma; proliferation; proximal tubular epithelia; reactive oxygen species; renin-angiotensin system; systemic RAS; translocatio; tubulointerstitial; unequivocal statement; xanthine oxidase

Document Type: Research Article

Publication date: 01 December 2010

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content